SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

CHRS

Coherus Oncology, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor the upcoming FDA alignment on tagmokitug's expedited development path in second-line esophageal cancer and the trajectory of LOQTORZI revenue growth toward the $25M-$30M quarterly core cash burn breakeven target.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CHRS drug pipeline →

LOQTORZI

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available in the U.S. since October 2023.
Next catalyst
None dated

What to watchLOQTORZI is a commercial-stage asset generating growing but still modest revenue (Q2 2026 net sales of $13.6M, up 15% sequentially). The company reported Q3 2026 results on November 9, 2026 with a $39.3M net loss and announced a strategic prioritization plan focusing on tagmokitug/toripalimab for esophageal cancer. Watch for Q3 LOQTORZI revenue trajectory and any updates on the expedited esophageal cancer development path. The stock trades near $0.84, down from a 52-week high of $2.62, reflecting the company's cash burn and pipeline-stage focus beyond LOQTORZI.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6409
T+0 close · Nov 9, 2026 · via day close
Latest settled
−9.11%
T+1 · $0.5825 · next T+5 in 4h
Vs SPY
−10.43%
α at T+1
Latest observation
−17.35%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $0.6409entry
  2. T+1 · 6d ago −9.11%α −10.43% · $0.5825
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a non-GAAP net loss of $(0.20) per share, beating the consensus estimate of $(0.21). The company announced a strategic prioritization of tagmokitug in esophageal cancer, a ~30% headcount reduction, and guided to lower quarterly cash burn of $6M-$7M. Cash and equivalents fell to $83.6M from $172.1M at year-end 2025.

Key Financial Metrics

EPS (Adj.)
−$0.20
est −$0.21 · +4.8% · GAAP: $-0.25
Revenue
$14.3M
est $15.9M · -10.2% · +23.4% YoY
Rating
in line

Key Facts

  • Q3 2026 net revenue $14.3M vs $11.6M YoY (+23%)
  • Non-GAAP EPS $(0.20) vs consensus $(0.21) (beat)
  • LOQTORZI net revenue $14.0M, up 25% YoY
  • Headcount reduction of ~30% to lower core cash burn by $6M-$7M quarterly
  • Cash and marketable securities $83.6M as of Sep 30, 2026, down from $172.1M at Dec 31, 2025
  • Net loss from continuing operations $(38.9M) vs $(44.5M) YoY
  • R&D expenses $22.6M, down from $27.3M YoY
  • SG&A expenses $21.2M, down from $24.9M YoY
  • Company focusing tagmokitug development on esophageal cancer, deprioritizing other indications

Financial Impact

Revenue $14.3M, non-GAAP net loss $(31.2M), cash burn reduction guided to $6M-$7M quarterly

revenueepscash burnoperating expenses

Risk Factors

  • Cash runway limited to ~2-3 quarters at current burn rate without additional financing
  • Strategic pivot to esophageal cancer carries clinical and regulatory execution risk
  • LOQTORZI revenue growth may not reach self-sufficiency targets
  • Headcount reduction may impact operational capacity

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398986

Track record

15 reports on CHRS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026